Cargando…

Treatment of a recurrent ischial ulcer with injected exosomes

Pressure ulcers (PUs) affect 2.5 million patients per year. Even after successful reconstruction, 50% of PUs recur. Patients with multiply recurrent PUs eventually consume all locoregional donor sites. This underscores the need for novel, less invasive approaches in PU reconstruction. Here, we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Messa, Genevieve E, Tiongco, Rafael P, Lau, Frank H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238301/
https://www.ncbi.nlm.nih.gov/pubmed/35774473
http://dx.doi.org/10.1093/jscr/rjac271
_version_ 1784737018148814848
author Messa, Genevieve E
Tiongco, Rafael P
Lau, Frank H
author_facet Messa, Genevieve E
Tiongco, Rafael P
Lau, Frank H
author_sort Messa, Genevieve E
collection PubMed
description Pressure ulcers (PUs) affect 2.5 million patients per year. Even after successful reconstruction, 50% of PUs recur. Patients with multiply recurrent PUs eventually consume all locoregional donor sites. This underscores the need for novel, less invasive approaches in PU reconstruction. Here, we report the first successful use of mesenchymal stem cell exosomes in PU reconstruction. The patient presented with a right ischial ulcer that persisted despite 9 months of wound care and appropriate antibiotic therapy. After six subcutaneous ExoFlo exosome injections over 8 weeks, the PU was completely healed. Additional studies of this promising technology should be performed.
format Online
Article
Text
id pubmed-9238301
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92383012022-06-29 Treatment of a recurrent ischial ulcer with injected exosomes Messa, Genevieve E Tiongco, Rafael P Lau, Frank H J Surg Case Rep Case Report Pressure ulcers (PUs) affect 2.5 million patients per year. Even after successful reconstruction, 50% of PUs recur. Patients with multiply recurrent PUs eventually consume all locoregional donor sites. This underscores the need for novel, less invasive approaches in PU reconstruction. Here, we report the first successful use of mesenchymal stem cell exosomes in PU reconstruction. The patient presented with a right ischial ulcer that persisted despite 9 months of wound care and appropriate antibiotic therapy. After six subcutaneous ExoFlo exosome injections over 8 weeks, the PU was completely healed. Additional studies of this promising technology should be performed. Oxford University Press 2022-06-28 /pmc/articles/PMC9238301/ /pubmed/35774473 http://dx.doi.org/10.1093/jscr/rjac271 Text en Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Messa, Genevieve E
Tiongco, Rafael P
Lau, Frank H
Treatment of a recurrent ischial ulcer with injected exosomes
title Treatment of a recurrent ischial ulcer with injected exosomes
title_full Treatment of a recurrent ischial ulcer with injected exosomes
title_fullStr Treatment of a recurrent ischial ulcer with injected exosomes
title_full_unstemmed Treatment of a recurrent ischial ulcer with injected exosomes
title_short Treatment of a recurrent ischial ulcer with injected exosomes
title_sort treatment of a recurrent ischial ulcer with injected exosomes
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238301/
https://www.ncbi.nlm.nih.gov/pubmed/35774473
http://dx.doi.org/10.1093/jscr/rjac271
work_keys_str_mv AT messagenevievee treatmentofarecurrentischialulcerwithinjectedexosomes
AT tiongcorafaelp treatmentofarecurrentischialulcerwithinjectedexosomes
AT laufrankh treatmentofarecurrentischialulcerwithinjectedexosomes